Option Care Health (NASDAQ:OPCH) Updates FY 2026 Earnings Guidance

Option Care Health (NASDAQ:OPCH) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.820-1.920 for the period, compared to the consensus estimate of 1.830. The company issued revenue guidance of $5.7 billion-$5.8 billion, compared to the consensus revenue estimate of $5.9 billion.

Option Care Health Price Performance

OPCH stock traded down $6.54 during midday trading on Thursday, reaching $20.33. 17,276,087 shares of the stock were exchanged, compared to its average volume of 1,641,903. Option Care Health has a 52 week low of $18.01 and a 52 week high of $36.80. The company has a fifty day moving average price of $29.15 and a 200 day moving average price of $30.69. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.53 and a quick ratio of 0.96. The stock has a market capitalization of $3.19 billion, a PE ratio of 15.88, a P/E/G ratio of 1.50 and a beta of 0.95.

Option Care Health (NASDAQ:OPCH) last posted its earnings results on Thursday, April 30th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.39 by $0.01. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.40 billion. Option Care Health had a return on equity of 18.57% and a net margin of 3.67%.The business’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period last year, the company earned $0.40 earnings per share. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. As a group, analysts expect that Option Care Health will post 1.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on OPCH. Morgan Stanley boosted their target price on shares of Option Care Health from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, January 13th. Barrington Research lifted their price target on shares of Option Care Health from $38.00 to $42.00 and gave the stock an “outperform” rating in a report on Friday, January 16th. Wall Street Zen cut shares of Option Care Health from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Truist Financial set a $40.00 price objective on Option Care Health in a report on Tuesday, January 13th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Option Care Health in a research report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Option Care Health has a consensus rating of “Moderate Buy” and an average target price of $37.00.

Option Care Health News Summary

Here are the key news stories impacting Option Care Health this week:

• Positive Sentiment: Q1 EPS slightly beat consensus: Option Care reported $0.40 EPS vs. consensus ~ $0.39, matching prior‑year EPS — a modest pocket of positive surprise. Q1 Earnings Beat (Zacks)
• Neutral Sentiment: Calls and disclosures available: the company held an earnings call and filed a press release/slide deck with details—useful for parsing management commentary and assumptions behind guidance. Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Revenue miss in Q1 and full‑year revenue guidance trimmed: Q1 revenue $1.35B vs. estimates ~$1.40B, and FY‑2026 revenue guide narrowed to ~$5.7–5.8B versus street ~$5.9B — the revenue shortfall and guide cut are the primary catalysts for the selloff. Revenue Miss & Stock Slide (Seeking Alpha)
• Negative Sentiment: Legal/investigator overhang: multiple plaintiff firms and a securities‑law investigation (Holzer & Holzer, Block & Leviton, Johnson Fistel) have announced inquiries tied to the results and guidance, increasing short‑term uncertainty and potential legal costs. Holzer Investigation (GlobeNewswire) Block & Leviton Alert (GlobeNewswire) Johnson Fistel Alert (GlobeNewswire)
• Negative Sentiment: Market reaction and volume: the stock sold off sharply on heavy volume after the release, reflecting investor concern about revenue momentum and the added legal overhang. Market Reaction (Yahoo)

Hedge Funds Weigh In On Option Care Health

A number of hedge funds have recently bought and sold shares of the company. Royal Bank of Canada lifted its position in shares of Option Care Health by 20.7% during the 1st quarter. Royal Bank of Canada now owns 231,161 shares of the company’s stock valued at $8,078,000 after acquiring an additional 39,661 shares during the period. AQR Capital Management LLC increased its stake in Option Care Health by 162.6% in the first quarter. AQR Capital Management LLC now owns 41,633 shares of the company’s stock valued at $1,450,000 after purchasing an additional 25,777 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Option Care Health during the first quarter valued at about $208,000. Invesco Ltd. boosted its position in shares of Option Care Health by 2.7% during the 2nd quarter. Invesco Ltd. now owns 294,363 shares of the company’s stock worth $9,561,000 after purchasing an additional 7,678 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Option Care Health by 528.1% in the second quarter. EverSource Wealth Advisors LLC now owns 1,407 shares of the company’s stock valued at $46,000 after acquiring an additional 1,183 shares in the last quarter. Institutional investors own 98.05% of the company’s stock.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.